Literature DB >> 12771946

A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells.

Michel Jourdan1, Jean-Luc Veyrune, John De Vos, Nicole Redal, Guilhem Couderc, Bernard Klein.   

Abstract

Interleukin-6 (IL-6) is a major survival factor for malignant plasma cells involved in multiple myeloma. Using an RNase protection assay, we looked for gene expression of 10 anti- and proapoptotic Bcl-2-family proteins in 12 IL-6-dependent human myeloma cell lines (HMCL). A high Mcl-1 gene expression was found in all HMCLs and the other genes were variably expressed. Out of the 10 Bcl-2-family members, only the Mcl-1 gene was regulated by IL-6. Upon starvation of IL-6, Mcl-1 gene expression decreased in association with myeloma cell apoptosis and was upregulated after adding IL-6 again in association with myeloma cell survival. A constitutive Mcl-1 expression was induced with an Mcl-1-GFP retrovirus in two IL-6-dependent HMCLs. The Mcl-1 HMCLs have a marked reduced apoptosis upon IL-6 starvation compared to HMCLs transduced with control GFP retrovirus and may grow without adding IL-6. These data emphasize the major role of Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12771946      PMCID: PMC2396235          DOI: 10.1038/sj.onc.1206423

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  41 in total

1.  Overexpression of Mcl-1 in anaplastic large cell lymphoma cell lines and tumors.

Authors:  George Z Rassidakis; Raymond Lai; Timothy J McDonnell; Fernando Cabanillas; Andreas H Sarris; L Jeffrey Medeiros
Journal:  Am J Pathol       Date:  2002-06       Impact factor: 4.307

2.  Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6.

Authors:  B Klein; X G Zhang; M Jourdan; J Content; F Houssiau; L Aarden; M Piechaczyk; R Bataille
Journal:  Blood       Date:  1989-02       Impact factor: 22.113

3.  Novel evidence of a role for chromosome 1 pericentric heterochromatin in the pathogenesis of B-cell lymphoma and multiple myeloma.

Authors:  P Le Baccon; D Leroux; C Dascalescu; S Duley; D Marais; E Esmenjaud; J J Sotto; M Callanan
Journal:  Genes Chromosomes Cancer       Date:  2001-11       Impact factor: 5.006

4.  Myeloid cell factor-1 is a critical survival factor for multiple myeloma.

Authors:  Bin Zhang; Ivana Gojo; Robert G Fenton
Journal:  Blood       Date:  2002-03-15       Impact factor: 22.113

5.  Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.

Authors:  Constantine S Mitsiades; Nicholas Mitsiades; Vassiliki Poulaki; Robert Schlossman; Masaharu Akiyama; Dharminder Chauhan; Teru Hideshima; Steven P Treon; Nikhil C Munshi; Paul G Richardson; Kenneth C Anderson
Journal:  Oncogene       Date:  2002-08-22       Impact factor: 9.867

6.  Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts.

Authors:  Karin Tarte; John De Vos; Thomas Thykjaer; Fenghuang Zhan; Geneviève Fiol; Valérie Costes; Thierry Rème; Eric Legouffe; Jean-François Rossi; John Shaughnessy; Torben F Ørntoft; Bernard Klein
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

7.  Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells.

Authors:  Sophie Derenne; Brett Monia; Nicholas M Dean; Jennifer K Taylor; Marie-Josée Rapp; Jean-Luc Harousseau; Régis Bataille; Martine Amiot
Journal:  Blood       Date:  2002-07-01       Impact factor: 22.113

8.  IgG1 plasmacytosis in interleukin 6 transgenic mice.

Authors:  S Suematsu; T Matsuda; K Aozasa; S Akira; N Nakano; S Ohno; J Miyazaki; K Yamamura; T Hirano; T Kishimoto
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

9.  Establishment of two interleukin 6 (B cell stimulatory factor 2/interferon beta 2)-dependent human bone marrow-derived myeloma cell lines.

Authors:  S Shimizu; R Yoshioka; Y Hirose; S Sugai; J Tachibana; S Konda
Journal:  J Exp Med       Date:  1989-01-01       Impact factor: 14.307

10.  Increased MCL-1 expression is associated with poor prognosis in ovarian carcinomas.

Authors:  Kazushi Shigemasa; Osamu Katoh; Yuko Shiroyama; Shoji Mihara; Keiji Mukai; Nobutaka Nagai; Koso Ohama
Journal:  Jpn J Cancer Res       Date:  2002-05
View more
  49 in total

1.  Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome.

Authors:  Rodger E Tiedemann; Yuan Xao Zhu; Jessica Schmidt; Chang Xin Shi; Chris Sereduk; Hongwei Yin; Spyro Mousses; A Keith Stewart
Journal:  Cancer Res       Date:  2011-12-06       Impact factor: 12.701

2.  High expression of Mcl-1 in ALK positive and negative anaplastic large cell lymphoma.

Authors:  R Rust; G Harms; T Blokzijl; M Boot; A Diepstra; J Kluiver; L Visser; S-C Peh; M Lim; W A Kamps; S Poppema; A van den Berg
Journal:  J Clin Pathol       Date:  2005-05       Impact factor: 3.411

3.  The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.

Authors:  Mark F van Delft; Andrew H Wei; Kylie D Mason; Cassandra J Vandenberg; Lin Chen; Peter E Czabotar; Simon N Willis; Clare L Scott; Catherine L Day; Suzanne Cory; Jerry M Adams; Andrew W Roberts; David C S Huang
Journal:  Cancer Cell       Date:  2006-11       Impact factor: 31.743

4.  Gene expression of anti- and pro-apoptotic proteins in malignant and normal plasma cells.

Authors:  Michel Jourdan; Thierry Reme; Hartmut Goldschmidt; Geneviève Fiol; Véronique Pantesco; John De Vos; Jean-François Rossi; Dirk Hose; Bernard Klein
Journal:  Br J Haematol       Date:  2009-01-08       Impact factor: 6.998

5.  Autocrine amplification of immature myeloid cells by IL-6 in multiple myeloma-infiltrated bone marrow.

Authors:  T Matthes; B Manfroi; A Zeller; I Dunand-Sauthier; B Bogen; B Huard
Journal:  Leukemia       Date:  2015-06-19       Impact factor: 11.528

6.  The Bcl-2 family member Bfl-1/A1 is strongly repressed in normal and malignant plasma cells but is a potent anti-apoptotic factor for myeloma cells.

Authors:  Karin Tarte; Michel Jourdan; Jean Luc Veyrune; Ingolf Berberich; Geneviève Fiol; Nicole Redal; John Shaughnessy; Bernard Klein
Journal:  Br J Haematol       Date:  2004-05       Impact factor: 6.998

7.  BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone.

Authors:  Jérôme Moreaux; Eric Legouffe; Eric Jourdan; Philippe Quittet; Thierry Rème; Cécile Lugagne; Philippe Moine; Jean-François Rossi; Bernard Klein; Karin Tarte
Journal:  Blood       Date:  2003-12-04       Impact factor: 22.113

Review 8.  Targeting the apoptosis pathway in hematologic malignancies.

Authors:  Shadia Zaman; Rui Wang; Varsha Gandhi
Journal:  Leuk Lymphoma       Date:  2014-02-04

9.  Induction of the interleukin 6/ signal transducer and activator of transcription pathway in the lungs of mice sub-chronically exposed to mainstream tobacco smoke.

Authors:  Sabina Halappanavar; Marsha Russell; Martin R Stampfli; Andrew Williams; Carole L Yauk
Journal:  BMC Med Genomics       Date:  2009-08-21       Impact factor: 3.063

10.  Nitric oxide induces cell death by regulating anti-apoptotic BCL-2 family members.

Authors:  Colleen M Snyder; Emelyn H Shroff; Jing Liu; Navdeep S Chandel
Journal:  PLoS One       Date:  2009-09-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.